The India Pharmaceutical Market Strategic Intelligence Suite 2026–2031 comprises two full-length strategic research reports viewed together for the first time - the India Pharmaceuticals Manufacturing Report (production/supply side) and the India Pharmaceuticals Industry Report (consumption/demand side) - plus this summary and accompanying presentation and infographic.
Most market research covers only one side of the pharmaceutical value chain - either the drug market (revenue, prescribing, pricing) or pharmaceutical manufacturing (production, capacity, exports). This suite covers both, from the same rigorously verified data foundation of company annual reports and official investor relations disclosures, and integrates the two perspectives into a single comparative strategic intelligence resource.
The India Pharmaceuticals Industry Strategic Research Report [2] (consumption/demand-side) was valued at $27.8 billion in 2025 and is projected to reach $50.0 billion by 2031, a CAGR of 8.4%, with the GLP-1 sub-segment the single fastest-growing category at a real, IPM-tracked 37.7% CAGR. Seventeen companies are profiled in depth, all independently verified against official investor relations disclosures.
The India Pharmaceuticals Manufacturing Market Strategic Research Report [3] (production/supply-side) was valued at $30.5 billion in 2025 and is projected to reach $55.5 billion by 2031, a CAGR of 10.5% - meaningfully faster than the demand side. Real, PharmExcil-confirmed pharmaceutical exports reached $31.11 billion in FY2026, more than double FY2014's $15.44 billion. Eighteen companies are profiled, including four dedicated CDMO/API specialists (Divi's Laboratories, Gland Pharma, Granules India, and Jubilant Pharmova) not covered in the demand-side report.
The single most important finding when viewing both reports together is structural: India's pharmaceutical manufacturing output grows at a meaningfully higher CAGR (10.5%) than domestic drug-market consumption (8.4%). This divergence is real and driven by three factors: real export growth (PharmExcil-confirmed exports more than doubling since FY2014), a real, data-verified manufacturing geography shift (South India's Hyderabad API cluster now nearly rivals West India's Gujarat/Maharashtra base, 39.8% vs. 38.6% of manufacturing share), and uneven but real Production-Linked Incentive (PLI) scheme capacity investment (44% disbursement on finished formulations versus 1.3% on Bulk Drugs/API specifically).
| Component | Content | Pages |
|---|---|---|
| Report 1: Industry Report | Drug market revenue, therapy segments, distribution channels, 17 officially-verified companies | 264 |
| Report 2: Manufacturing Report | Production, exports, PLI scheme, CDMO, 18 officially-verified companies | 251 |
| Executive Presentation | 10-slide integrated comparative presentation | 10 slides |
| Summary Document (DOCX) | Integrated executive summary of both reports' headline findings | 4 pages |
| Interactive Infographic (HTML) | Visual one-page infographic for digital distribution | 1 page |
Please Note: individual reports can also be purchased separately based on your specific data needs.
Sun Pharmaceutical, Aurobindo Pharma, Dr. Reddy's Labs, Cipla, Lupin, Zydus Lifesciences, Biocon, Alkem Laboratories, Torrent Pharma, Divi's Laboratories, Piramal Pharma, Mankind Pharma, Gland Pharma, Ipca Laboratories, Granules India, Jubilant Pharmova, Ajanta Pharma, Natco Pharma, Abbott India, Pfizer India, Sanofi India
*If Applicable.
NAVADHI is a market research company that helps global firms differentiate themselves, break market entry barriers, track their investments, develop business strategies and plan for future by providing actionable market research intelligence that helps them succeed.